Accelerated Early Phase Decision-Making – Insider Insights to Speed Development

Published on: Jan 7, 2025

Access insider insights from combined perspectives of clinical pharmacology, global regulatory considerations, and private equity investors on accelerating early development timelines to go/no go decisions and early proof of concept, without shortcuts. Parexel’s early phase team and EQT LifeSciences share best practices for combining sequential early phase studies into a single protocol.

Return to Insights Center

Related Insights

Playbook

Streamlining development in the EU: Strategies for smoother CTA submissions

Feb 27, 2025

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Webinar

Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development

May 6, 2025

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Article

Maximize the efficiency of regulatory operations with five key competencies

Jul 23, 2021

Blog

Focusing on value drivers to reduce risk in early-stage drug development

Jan 6, 2025

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Related Insights

Playbook

Streamlining development in the EU: Strategies for smoother CTA submissions

Feb 27, 2025

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Webinar

Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development

May 6, 2025

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Article

Maximize the efficiency of regulatory operations with five key competencies

Jul 23, 2021

Blog

Focusing on value drivers to reduce risk in early-stage drug development

Jan 6, 2025

Show more